Hepatocyte-Targeted Lipid Construct for Insulin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin formulations for managing Type I and Type II diabetes do not effectively target insulin delivery to hepatocytes, leading to inadequate glucose control, as they release insulin at a constant rate without specific targeting to the liver.
Innovation Solution
A lipid construct comprising an amphipathic lipid and an extended amphipathic lipid, which targets insulin to hepatocytes, allowing for a controlled release of insulin over time, providing both long-acting basal insulin and meal-time hepatic insulin stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If insulin is released at a constant rate throughout the day from subcutaneous tissue, then insulin bioavailability is sustained, but insulin is distributed to a wide range of systems rather than being targeted to the liver
Solution Approach 1:
The patent uses hepatocyte-targeting ligands (such as asialoglycoprotein receptor ligands) as intermediaries to direct insulin from the subcutaneous injection site specifically to hepatocytes in the liver. These ligands act as mediators that bind to insulin and facilitate its selective uptake by liver cells, resolving the contradiction between sustained release and targeted delivery.
Solution Approach 2:
The invention creates different functional zones within the insulin formulation: a targeting component that directs insulin to the liver and a release component that controls the timing of insulin release. This local differentiation of functions within the formulation enables both sustained bioavailability and hepatic targeting simultaneously.
2Reliability
If multiple daily injections of insulin are administered to control blood glucose levels, then glucose control is achieved, but the complexity of treatment increases
Solution Approach 1:
The patent employs insulin formulations with different release kinetics (rapid-acting, intermediate-acting, and long-acting components) that dynamically match the body's insulin needs throughout the day and night. This dynamic release profile allows for better glucose control with fewer injections by mimicking physiological insulin secretion patterns.
Solution Approach 2:
The invention creates multi-functional insulin formulations that combine basal insulin provision with mealtime insulin coverage in single products. These formulations serve multiple functions (basal control, prandial control, and hepatic targeting) simultaneously, reducing the number of separate injections required while maintaining effective glucose control.
3Duration of action of moving object
If insulin formulations attempt to delay and control bio-distribution by regulating release to peripheral tissues, then sustained insulin bioavailability is achieved, but the ability to target insulin to the liver is lost
Solution Approach 1:
The patent segments the insulin molecule or formulation into distinct functional components: a release-controlling component (such as zinc complexes or protamine salts that control release kinetics) and a targeting component (hepatocyte-specific ligands). This segmentation allows each component to independently perform its function—sustained release and hepatic targeting—without interfering with the other.
Solution Approach 2:
The invention creates composite insulin formulations that combine multiple materials with different properties: release-modifying materials (zinc, protamine, pH-responsive polymers) and targeting materials (asialoglycoprotein receptor ligands, transferrin conjugates). This composite approach enables the formulation to exhibit both sustained release characteristics and hepatic targeting capability simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances glucose control by delivering insulin specifically to the liver, offering a dynamic equilibrium process that normalizes glucose concentrations in diabetic patients, providing both long-acting and meal-time glucose management.
Implementation Method 1
the distal moiety targets the construct to a receptor displayed by a hepatocyte
Implementation Method 2
The lipid construct releases free insulin over time as well as targets a portion of the remaining insulin to the hepatocytes in the liver
Data Source
AI summary
The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.